Bipolar Disorder Clinical Trial
Official title:
A Double-Blind, Placebo Controlled Augmentation Study With Allopurinol for Treatment Resistant Mania
The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for treatment resistant mania and mixed mania.
Bipolar disorder is a severe mental disorder with episodes of mania and depression. Current
medications for mania can have significant side effects, high costs and the need for blood
monitoring. The purpose of this research study is to study the effectiveness of allopurinol,
in combination with lithium or valproic acid or carbamazepine, for treatment-resistant
bipolar mania and mixed mania. This research study is designed to test the safety and/or
effectiveness of allopurinol that has been approved by the U.S. Food and Drug Administration
(FDA) for recurrent calcium renal calculus, gout, hyperuricemia (cancer and tumor lysis
syndrome), but it is not approved for use in treatment-resistant bipolar mania or mixed
mania.
Participants in this double-blind study will be randomly assigned to one of two study groups.
The first group will receive the study medication of allopurinol while the second group will
receive a placebo. These will be taken in conjunction with current medications and doses. The
study will last for 7 weeks (an initial screening, a baseline visit and 4 follow-up visits at
weeks 1,2,4, and 6). The initial screening visit will be used to determine whether or not the
subject is able to participate in the study. The following will be conducted during the
screening visit: Review of medical and psychiatric history along with standard psychiatric
assessment exams; Physical examination, including review of prior and current medications and
adverse drug effects; An electrocardiogram (ECG) - a painless test which is done by attaching
straps or pads to your limbs and chest and recording the electrical pattern of your heart,
will be done to record your heart rhythm; About 5 tablespoons of blood will be drawn to
assess basic laboratory values that show if you are healthy enough to participate in the
study; Blood levels of lithium, valproic acid, and/or carbamazepine will be measured; A urine
sample will be collected to test for the presence of illegal drugs and for pregnancy test (if
you are a female of child-bearing potential); Collection of demographic data (e.g., age,
gender, marital status, social and vocational status) and other information including health
beliefs, and knowledge of illness. At the baseline visit the participant will be given
questionnaires related to mood, quality of life, disability, medications, and side effects.
The participant's vitals (temperature, weight, heart rate, and blood pressure) will be
measured. The participant will be randomized to treatment (300 mg of allopurinol/day) or
placebo. After week one at the Week 1 visit, those that have tolerated the dosage of
allopurinol will get an increased dosage. The participant will also complete a set of
questionnaires. Vitals will be taken. The remaining follow-up visits will be similar to visit
one except that there will be no more increases in dosage; Week 2 will include a blood draw
to measure levels of lithium, valproic acid, and/or carbamazepine in the participant's blood,
and the final visit at Week 6 will in addition include a blood draw, and exit physical exam,
and a urine sample will be collected.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT02855762 -
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder
|
N/A | |
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT02513654 -
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
|
Phase 1 | |
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT02212041 -
Electronic Cigarettes in Smokers With Mental Illness
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Not yet recruiting |
NCT04432116 -
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
|
N/A | |
Terminated |
NCT02909504 -
Gao NARASD Lithium Study
|
Phase 4 | |
Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
Terminated |
NCT02893371 -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
|
||
Recruiting |
NCT03088657 -
Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
|
||
Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 |